From the brief review of FDA approved drugs that possess p-gp inhibition activity, we highlight several candidates such as chlorpromazine and sildenafil that could have potential for further development, utilizing its role of p-gp inhibitor to enhance the potency of tumor cytotoxic agents. This evidence concerns the gene PGP and neoplasm.